Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications

Jeffrey Betcher, Elizabeth Dow, Nandita D Khera

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the need for proactive involvement of all stakeholders to optimize adherence for successful use of these agents are increasingly being recognized. The current reactive model is negatively impacting the patient experience through delays in care, financial toxicity, and decreased safety. It also impacts the healthcare providers in the form of lost revenue and staff burnout due to labor-intensive procurement and patient financial assistance burdens. In this review, we describe some of the issues identified and discuss potential strategies to improve patient access, minimize healthcare burden, and review current policy initiatives and patient advocacy efforts to reduce financial toxicity.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCurrent Hematologic Malignancy Reports
DOIs
StateAccepted/In press - Apr 16 2016

Keywords

  • Medication adherence
  • Oral anticancer drugs
  • Oral cancer therapy
  • Oral chemotherapy
  • Oral parity
  • Pharmacoeconomics

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Oral Chemotherapy in Patients with Hematological Malignancies—Care Process, Pharmacoeconomic and Policy Implications'. Together they form a unique fingerprint.

  • Cite this